Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Inhibikase Therapeutics Inc
IKT
Healthcare
Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease...
inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:IKT)
New Post
View:
Posts & Comments
Threaded Posts
(8)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 02, 2024 6:16am
Inhibikase Therapeutics, Inc. (NASDAQ:IKT): Advancing Innova
https://beyondspx.com/2024/08/01/inhibikase-therapeutics-inc-nasdaqikt-advancing-innovative-therapies-for-parkinsons-and-beyond/
(165)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 20, 2024 3:30pm
Inhibikase Therapeutics Announces Pricing of Registered Dire
News; $IKT Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionBOSTON and ATLANTA, May 20
...more
(65)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 16, 2023 9:10am
My U.S w/l this a.m......
CS....HUBC...IKT...LIPO...THMO
(65)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 08, 2023 10:19am
IKT ....Vols have declined
JUst an observation...no position Still watching !
(65)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 08, 2023 9:33am
IKT .... Vol spike post halt this a.m ... + NR
ON watch
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >